MADRIGAL PHARMACEUTICALS, INC. Comprehensive Income
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Comprehensive Income of -$58.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$58.21M.
- MADRIGAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$94.18M.
- MADRIGAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$58.77M.
- MADRIGAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$114.23M.
- MADRIGAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$287.88M.
- MADRIGAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$465.89M.
- MADRIGAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$373.13M.
- MADRIGAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$295.30M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$58.21M 10-Q · filed 2026-07-30 | -$152.40M 10-Q · filed 2026-07-30 | -$211.16M derived: sum of 3 quarters · filed 2026-07-30 | -$325.40M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | -$94.18M 10-Q · filed 2026-05-06 | -$152.95M derived: sum of 2 quarters · filed 2026-05-06 | -$267.19M derived: sum of 3 quarters · filed 2026-05-06 | -$308.74M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | -$58.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$173.00M derived: sum of 2 quarters · filed 2026-02-19 | -$214.56M derived: sum of 3 quarters · filed 2026-07-30 | -$287.88M 10-K · filed 2026-02-19 | ||||
| 2025-09-30 | -$114.23M 10-Q · filed 2025-11-04 | -$155.79M derived: sum of 2 quarters · filed 2026-07-30 | -$229.11M 10-Q · filed 2025-11-04 | -$289.33M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | -$41.56M 10-Q · filed 2026-07-30 | -$114.88M 10-Q · filed 2026-07-30 | -$175.09M derived: sum of 3 quarters · filed 2026-07-30 | -$280.42M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | -$73.32M 10-Q · filed 2026-05-06 | -$133.54M derived: sum of 2 quarters · filed 2026-05-06 | -$238.86M derived: sum of 3 quarters · filed 2026-05-06 | -$391.03M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$60.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$165.54M derived: sum of 2 quarters · filed 2026-02-19 | -$317.71M derived: sum of 3 quarters · filed 2026-02-19 | -$465.89M 10-K · filed 2026-02-19 | ||||
| 2024-09-30 | -$105.33M 10-Q · filed 2025-11-04 | -$257.49M derived: sum of 2 quarters · filed 2025-11-04 | -$405.67M 10-Q · filed 2025-11-04 | -$517.36M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-06-30 | -$152.17M 10-Q · filed 2025-08-05 | -$300.35M 10-Q · filed 2025-08-05 | -$412.03M derived: sum of 3 quarters · filed 2026-02-19 | -$510.73M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-03-31 | -$148.18M 10-Q · filed 2025-05-01 | -$259.87M derived: sum of 2 quarters · filed 2026-02-19 | -$358.56M derived: sum of 3 quarters · filed 2026-02-19 | -$444.36M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2023-12-31 | -$111.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$210.38M derived: sum of 2 quarters · filed 2026-02-19 | -$296.18M derived: sum of 3 quarters · filed 2026-02-19 | -$373.13M 10-K · filed 2026-02-19 | ||||
| 2023-09-30 | -$98.69M 10-Q · filed 2024-10-31 | -$184.50M derived: sum of 2 quarters · filed 2024-10-31 | -$261.45M 10-Q · filed 2024-10-31 | -$347.15M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | -$85.80M 10-Q · filed 2024-08-07 | -$162.75M 10-Q · filed 2024-08-07 | -$248.45M derived: sum of 3 quarters · filed 2025-02-26 | -$329.44M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | -$76.95M 10-Q · filed 2024-05-07 | -$162.65M derived: sum of 2 quarters · filed 2025-02-26 | -$243.64M derived: sum of 3 quarters · filed 2025-02-26 | -$314.41M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | -$85.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$166.69M derived: sum of 2 quarters · filed 2025-02-26 | -$237.46M derived: sum of 3 quarters · filed 2025-02-26 | -$295.30M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | -$80.99M 10-Q · filed 2023-11-06 | -$151.76M derived: sum of 2 quarters · filed 2023-11-06 | -$209.60M 10-Q · filed 2023-11-06 | -$274.24M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | -$70.78M 10-Q · filed 2023-08-08 | -$128.62M 10-Q · filed 2023-08-08 | -$193.25M derived: sum of 3 quarters · filed 2024-02-28 | -$256.36M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | -$57.84M 10-Q · filed 2023-05-09 | -$122.47M derived: sum of 2 quarters · filed 2024-02-28 | -$185.58M derived: sum of 3 quarters · filed 2024-02-28 | -$247.21M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | -$64.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$127.74M derived: sum of 2 quarters · filed 2024-02-28 | -$189.37M derived: sum of 3 quarters · filed 2024-02-28 | -$241.97M 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | -$63.11M 10-Q · filed 2022-11-03 | -$124.73M derived: sum of 2 quarters · filed 2022-11-03 | -$177.34M 10-Q · filed 2022-11-03 | -$236.84M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-06-30 | -$61.62M 10-Q · filed 2022-08-04 | -$114.23M 10-Q · filed 2022-08-04 | -$173.73M derived: sum of 3 quarters · filed 2023-03-03 | -$232.35M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-03-31 | -$52.61M 10-Q · filed 2022-05-09 | -$112.10M derived: sum of 2 quarters · filed 2023-03-03 | -$170.73M derived: sum of 3 quarters · filed 2023-03-03 | -$219.08M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2020-12-31 | -$59.50M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-03 | -$118.12M derived: sum of 2 quarters · filed 2023-03-03 | -$166.48M derived: sum of 3 quarters · filed 2023-03-03 | -$202.41M 10-K/A · filed 2023-03-03 | ||||
| 2020-09-30 | -$58.62M 10-Q · filed 2021-11-04 | -$106.98M derived: sum of 2 quarters · filed 2021-11-04 | -$142.92M 10-Q · filed 2021-11-04 | -$170.73M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-06-30 | -$48.36M 10-Q · filed 2021-08-05 | -$84.29M 10-Q · filed 2021-08-05 | -$112.11M derived: sum of 3 quarters · filed 2022-02-24 | -$133.73M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-03-31 | -$35.94M 10-Q · filed 2021-05-06 | -$63.75M derived: sum of 2 quarters · filed 2022-02-24 | -$85.37M derived: sum of 3 quarters · filed 2022-02-24 | -$104.77M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2019-12-31 | -$27.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$49.44M derived: sum of 2 quarters · filed 2022-02-24 | -$68.83M derived: sum of 3 quarters · filed 2022-02-24 | -$83.41M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | -$21.62M 10-Q · filed 2020-11-05 | -$41.01M derived: sum of 2 quarters · filed 2020-11-05 | -$55.60M 10-Q · filed 2020-11-05 | -$67.25M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | -$19.39M 10-Q · filed 2020-08-06 | -$33.98M 10-Q · filed 2020-08-06 | -$45.63M derived: sum of 3 quarters · filed 2021-02-25 | -$54.24M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | -$14.58M 10-Q · filed 2020-05-07 | -$26.23M derived: sum of 2 quarters · filed 2021-02-25 | -$34.85M derived: sum of 3 quarters · filed 2021-02-25 | -$41.17M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | -$11.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$20.26M derived: sum of 2 quarters · filed 2021-02-25 | -$26.59M derived: sum of 3 quarters · filed 2021-02-25 | -$33.10M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | -$8.61M 10-Q · filed 2019-11-06 | -$14.94M derived: sum of 2 quarters · filed 2019-11-06 | -$21.45M 10-Q · filed 2019-11-06 | -$29.97M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | -$6.33M 10-Q · filed 2019-08-07 | -$12.84M 10-Q · filed 2019-08-07 | -$21.36M derived: sum of 3 quarters · filed 2020-02-26 | -$29.71M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | -$6.51M 10-Q · filed 2019-05-08 | -$15.03M derived: sum of 2 quarters · filed 2020-02-26 | -$23.38M derived: sum of 3 quarters · filed 2020-02-26 | -$31.76M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | -$8.52M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$16.88M derived: sum of 2 quarters · filed 2020-02-26 | -$25.25M derived: sum of 3 quarters · filed 2020-02-26 | -$31.21M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | -$8.35M 10-Q · filed 2018-11-06 | -$16.73M derived: sum of 2 quarters · filed 2018-11-06 | -$22.69M 10-Q · filed 2018-11-06 | -$30.40M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | -$8.38M 10-Q · filed 2018-08-07 | -$14.34M 10-Q · filed 2018-08-07 | -$22.05M derived: sum of 3 quarters · filed 2019-02-27 | -$36.11M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | -$5.96M 10-Q · filed 2018-05-08 | -$13.67M derived: sum of 2 quarters · filed 2019-02-27 | -$27.73M derived: sum of 3 quarters · filed 2019-02-27 | -$30.61M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | -$7.71M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$21.77M derived: sum of 2 quarters · filed 2019-02-27 | -$24.65M derived: sum of 3 quarters · filed 2019-02-27 | -$26.36M 10-K · filed 2019-02-27 | -$26.36M 10-K · filed 2017-03-31 | |||
| 2016-09-30 | -$14.06M 10-Q · filed 2017-11-09 | -$14.06M 10-Q · filed 2016-11-14 | -$16.94M derived: sum of 2 quarters · filed 2017-11-09 | -$18.65M 10-Q · filed 2017-11-09 | -$18.65M 10-Q · filed 2016-11-14 | -$20.53M derived: sum of 4 quarters · filed 2017-11-09 | ||
| 2016-06-30 | -$2.88M 10-Q · filed 2017-08-10 | -$3.30M 10-Q · filed 2016-07-20 | -$4.59M 10-Q · filed 2017-08-10 | -$9.83M 10-Q · filed 2016-07-20 | -$6.47M derived: sum of 3 quarters · filed 2017-08-10 | -$8.27M derived: sum of 4 quarters · filed 2017-08-10 | ||
| 2016-03-31 | -$1.71M 10-Q · filed 2017-05-11 | -$6.52M 10-Q · filed 2016-05-10 | -$3.60M derived: sum of 2 quarters · filed 2017-05-11 | -$5.40M derived: sum of 3 quarters · filed 2017-05-11 | -$25.21M derived: sum of 4 quarters · filed 2017-05-11 | |||
| 2015-12-31 | -$1.88M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-31 | -$3.68M derived: sum of 2 quarters · filed 2017-03-31 | -$23.49M derived: sum of 3 quarters · filed 2017-03-31 | -$6.84M 10-K · filed 2017-03-31 | -$68.67M 10-K · filed 2016-03-15 | |||
| 2015-09-30 | -$1.80M 10-Q/A · filed 2017-03-31 | -$17.61M 10-Q · filed 2015-11-05 | -$21.61M derived: sum of 2 quarters · filed 2017-03-31 | -$4.96M 10-Q/A · filed 2017-03-31 | -$58.13M 10-Q · filed 2015-11-05 | -$62.68M derived: sum of 4 quarters · filed 2017-03-31 | ||
| 2015-06-30 | -$19.81M 10-Q · filed 2016-07-20 | -$40.52M 10-Q · filed 2016-07-20 | -$60.88M derived: sum of 3 quarters · filed 2016-07-20 | -$80.83M derived: sum of 4 quarters · filed 2016-07-20 | ||||
| 2015-03-31 | -$20.70M 10-Q · filed 2016-05-10 | -$41.06M derived: sum of 2 quarters · filed 2016-05-10 | -$61.02M derived: sum of 3 quarters · filed 2016-05-10 | -$83.31M derived: sum of 4 quarters · filed 2016-05-10 | ||||
| 2014-12-31 | -$20.36M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$40.32M derived: sum of 2 quarters · filed 2016-03-15 | -$62.60M derived: sum of 3 quarters · filed 2016-03-15 | -$86.17M 10-K · filed 2016-03-15 | ||||
| 2014-09-30 | -$19.96M 10-Q · filed 2015-11-05 | -$42.24M derived: sum of 2 quarters · filed 2015-11-05 | -$65.81M 10-Q · filed 2015-11-05 | -$89.97M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-06-30 | -$22.29M 10-Q · filed 2015-08-06 | -$45.86M 10-Q · filed 2015-08-06 | -$70.01M derived: sum of 3 quarters · filed 2016-03-15 | -$92.53M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-03-31 | -$23.57M 10-Q · filed 2015-05-07 | -$47.72M derived: sum of 2 quarters · filed 2016-03-15 | -$70.24M derived: sum of 3 quarters · filed 2016-03-15 | -$93.02M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2013-12-31 | -$24.15M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$46.67M derived: sum of 2 quarters · filed 2016-03-15 | -$69.45M derived: sum of 3 quarters · filed 2016-03-15 | -$90.18M 10-K · filed 2016-03-15 | ||||
| 2013-09-30 | -$22.52M 10-Q · filed 2014-11-06 | -$45.30M derived: sum of 2 quarters · filed 2014-11-06 | -$66.03M 10-Q · filed 2014-11-06 | -$84.16M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-06-30 | -$22.79M 10-Q · filed 2014-08-06 | -$43.51M 10-Q · filed 2014-08-06 | -$61.64M derived: sum of 3 quarters · filed 2015-03-12 | -$76.63M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | -$20.72M 10-Q · filed 2014-05-08 | -$38.85M derived: sum of 2 quarters · filed 2015-03-12 | -$53.84M derived: sum of 3 quarters · filed 2015-03-12 | -$68.48M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | -$18.13M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$33.12M derived: sum of 2 quarters · filed 2015-03-12 | -$47.76M derived: sum of 3 quarters · filed 2015-03-12 | -$62.79M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | -$14.99M 10-Q · filed 2013-11-04 | -$29.63M derived: sum of 2 quarters · filed 2013-11-04 | -$44.66M 10-Q · filed 2013-11-04 | -$55.40M derived: sum of 4 quarters · filed 2014-03-11 | ||||
| 2012-06-30 | -$14.63M 10-Q · filed 2013-08-01 | -$29.67M 10-Q · filed 2013-08-01 | -$40.41M derived: sum of 3 quarters · filed 2014-03-11 | -$53.15M derived: sum of 4 quarters · filed 2014-03-11 | ||||
| 2012-03-31 | -$15.04M 10-Q · filed 2013-04-30 | -$25.78M derived: sum of 2 quarters · filed 2014-03-11 | -$38.52M derived: sum of 3 quarters · filed 2014-03-11 | -$51.01M derived: sum of 4 quarters · filed 2014-03-11 | ||||
| 2011-12-31 | -$10.74M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | -$23.48M derived: sum of 2 quarters · filed 2014-03-11 | -$35.98M derived: sum of 3 quarters · filed 2014-03-11 | -$47.37M 10-K · filed 2014-03-11 | ||||
| 2011-09-30 | -$12.74M 10-Q · filed 2012-11-06 | -$25.24M derived: sum of 2 quarters · filed 2012-11-06 | -$36.63M 10-Q · filed 2012-11-06 | |||||
| 2011-06-30 | -$12.49M 10-Q · filed 2012-08-02 | -$23.89M 10-Q · filed 2012-08-02 | ||||||
| 2011-03-31 | -$11.39M 10-Q · filed 2012-05-03 | |||||||
| 2010-12-31 | -$37.47M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |